Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

11.00 -0.18 (-1.61%)
Official Closing Price Updated: 7:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 356,533
Open 11.65
Bid (Size) 10.82 (1)
Ask (Size) 11.21 (1)
Prev. Close 11.18
Today's Range 10.92 - 11.95
52wk Range 1.600 - 12.19
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks are moving in today's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga

Performance

YTD
+151.1%
+151.1%
1 Month
+183.5%
+183.5%
3 Month
+257.1%
+257.1%
6 Month
+368.1%
+368.1%
1 Year
+166.3%
+166.3%

More News

Read More
Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session.
Via Chartmill
Gapping stocks in Monday's session
Via Chartmill
Alto Neuroscience Announces $50 Million Private Placement Financing
From Alto Neuroscience, Inc.
Via Business Wire
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
From Alto Neuroscience, Inc.
Via Business Wire
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug
Via Stocktwits
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Via Benzinga
This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO
Via NewMediaWire
Topics Fraud Lawsuit
ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANRO
Via NewMediaWire
Topics Fraud Lawsuit
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
From Faruqi & Faruqi LLP
Via GlobeNewswire
ANRO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
Investors in Alto Neuroscience, Inc. Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Via NewMediaWire
Topics Fraud Lawsuit
Investors in Alto Neuroscience, Inc. Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
Alto Neuroscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Via NewMediaWire
Topics Fraud Lawsuit
Alto Neuroscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is Alto Neuroscience, Inc. Common Stock publicly traded?
Yes, Alto Neuroscience, Inc. Common Stock is publicly traded.
What exchange does Alto Neuroscience, Inc. Common Stock trade on?
Alto Neuroscience, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Alto Neuroscience, Inc. Common Stock?
The ticker symbol for Alto Neuroscience, Inc. Common Stock is ANRO on the New York Stock Exchange
What is the current price of Alto Neuroscience, Inc. Common Stock?
The current price of Alto Neuroscience, Inc. Common Stock is 11.00
When was Alto Neuroscience, Inc. Common Stock last traded?
The last trade of Alto Neuroscience, Inc. Common Stock was at 10/24/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.